We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Radioembolization Microspheres Treat Hepatocellular Carcinoma

By MedImaging International staff writers
Posted on 29 Mar 2021
Print article
Image: A vial of TheraSphere contains millions of microscopic glass beads containing yttrium (Photo courtesy of Boston Scientific)
Image: A vial of TheraSphere contains millions of microscopic glass beads containing yttrium (Photo courtesy of Boston Scientific)
A selective internal radiation therapy (SIRT) platform delivers radioactive glass microspheres directly to liver tumors, with minimal exposure to surrounding healthy tissue.

Boston Scientific (Natick, MA, USA) TheraSphere treatment is a low toxicity SIRT comprised of millions of microscopic glass beads containing yttrium (Y-90) that are delivered to a Hepatocellular Carcinoma (HCC) through a catheter placed into the hepatic artery, which provides the main blood supply to the HCC. The microspheres, which are unable to traverse the tumor vasculature, are embolized within the tumor, exerting a local beta radiation radiotherapeutic effect, as the average range of the radiation in tissue is 2.5 mm, with a maximum range less than one centimeter.

TheraSphere is available in three dose sizes, each supplied with an administration set consisting of a single use, pre-assembled vial with inlet and outlet lines that facilitate infusion of the microspheres to the catheter. Each milligram of TheraSphere contains between 22,000 and 73,000 microspheres of Y-90. The treatment does not require hospitalization, and is typically performed as an outpatient procedure in as little as an hour. TheraSphere has been approved by the FDA after almost 20 years of humanitarian exemption device (HDE).

“The FDA approval will expand access to TheraSphere, which has demonstrated improvement in both survivability and quality of life through 20 years of clinical trials and real-world outcomes in the more than 70,000 patients globally,” said Peter Pattison, president of interventional oncology and peripheral interventions at Boston Scientific. “We expect to continue to focus our efforts on bringing this treatment to more patients, as well as further investigating the therapy for different cancer segments, including prostate and brain.”

As healthy liver tissue is mainly perfused by the portal vein, and most liver malignancies derive their blood supply from the hepatic artery, trans-arterial radioembolization (TARE) using radioactive Yttrium radioactive glass microspheres can be selectively administered to the tumors. The microspheres lodge in the small vessels of the tumor (embolization), emitting localized RT to targeted segments, results in tissue necrosis. The Y-90, with a half-life of 3.85 days, decays to Zirconium-90.

Related Links:
Boston Scientific


Print article
CIRS -  MIRION
Sun Nuclear -    Mirion

Channels

Radiography

view channel
Image: The FDA has cleared the CSA system with Dynamic Digital Radiography (Photo courtesy of 20/20 Imaging)

Advanced Digital X-Ray System Allows Clinicians to Capture and Visualize Anatomy in Motion

Dynamic Digital Radiography (DDR) is a revolutionary X-ray technology that enables the visualization of anatomy in motion, so clinicians can interpret the dynamic interaction of anatomical structures,... Read more

MRI

view channel
Image: MRI identifies patients with sarcoidosis at risk for bad cardiac outcomes (Photo courtesy of University of Minnesota Medical School)

MRI Identifies Patients at Higher Risk for Cardiac Sarcoidosis-Related Adverse Outcomes

Cardiac sarcoidosis is a rare inflammatory heart disease that can result in rhythm disturbances and heart failure. Researchers have now found that patients with certain features on magnetic resonance imaging... Read more

Ultrasound

view channel
Image: EG-740UT ultrasound endoscope combined with ARIETTA 850 provides outstanding ultrasound image quality (Photo courtesy of FUJIFILM)

Next-Gen Ultrasound Endoscope Enables Complex Diagnostic and Therapeutic Procedures

Endoscopic ultrasound is a specialist procedure performed utilizing an endoscope equipped with an ultrasonic transducer which emits and receives ultrasonic waves within the gastrointestinal tract, such... Read more

General/Advanced Imaging

view channel
Image: New guidance standardizes care for patients presenting with acute chest pain in the ED (Photo courtesy of Pexels)

New Guidance Recommends Coronary CTA as First-Line Test when Treating Acute Chest Pain in ED

Diagnosis and triage of emergency department (ED) patients with suspected acute coronary syndrome (ACS) consume a large and increasing amount of healthcare resources. ED overcrowding is associated with... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.